Praxis Precision Medicines (PRAX) News Today $73.68 +0.93 (+1.28%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down Following Insider SellingPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down on Insider SellingNovember 18 at 10:43 AM | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $146.33 Average Target Price from AnalystsNovember 18 at 2:07 AM | americanbankingnews.comCIBC Asset Management Inc Acquires 56,272 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)CIBC Asset Management Inc lifted its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 29.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 248,939 shares of the company's stock aftNovember 17, 2024 | marketbeat.comInsider Selling: Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Insider Sells 5,188 Shares of StockNovember 16, 2024 | insidertrades.comInsider Selling: Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Insider Sells 5,188 Shares of StockPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) insider Lauren Mastrocola sold 5,188 shares of the company's stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $81.78, for a total transaction of $424,274.64. Following the completion of the sale, the insider now directly owns 5,613 shares in the company, valued at approximately $459,031.14. This represents a 48.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.November 15, 2024 | marketbeat.comAlex Nemiroff Sells 8,239 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) StockPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) General Counsel Alex Nemiroff sold 8,239 shares of the stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $80.20, for a total transaction of $660,767.80. Following the sale, the general counsel now owns 10,301 shares of the company's stock, valued at $826,140.20. This trade represents a 44.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.November 15, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 7.9% - Should You Sell?Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 7.9% - Time to Sell?November 15, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by BrokeragesShares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have assigNovember 15, 2024 | marketbeat.comPiper Sandler Gives a Buy Rating to Praxis Precision Medicines (PRAX)November 13, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for PRAX FY2024 Earnings?November 13, 2024 | americanbankingnews.comWedbush Has Bearish Outlook for PRAX FY2024 EarningsNovember 12, 2024 | americanbankingnews.comFY2024 Earnings Estimate for PRAX Issued By HC WainwrightPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities researchers at HC Wainwright reduced their FY2024 earnings estimates for Praxis Precision Medicines in a research report issued on Thursday, November 7th. HC Wainwright analyst D. Tsao now expects that the company will post eNovember 11, 2024 | marketbeat.comEquities Analysts Offer Predictions for PRAX FY2024 EarningsPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Wedbush decreased their FY2024 earnings per share (EPS) estimates for Praxis Precision Medicines in a research note issued to investors on Wednesday, November 6th. Wedbush analyst L. Chico now anticipates that the company will post eaNovember 11, 2024 | marketbeat.comPraxis Precision Medicine (NASDAQ:PRAX) Stock, Insider Trading ActivityNovember 8, 2024 | benzinga.comPraxis Precision Medicine (NASDAQ:PRAX) Stock, Short Interest ReportNovember 8, 2024 | benzinga.comPraxis Precision Medicines: Strong Buy Rating Amid Potential Upside and Robust Pipeline Despite Operational ChallengesNovember 8, 2024 | markets.businessinsider.comPraxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsNovember 8, 2024 | finance.yahoo.comOptimistic Buy Rating for Praxis Precision Medicines Amid Strategic Pipeline Advancements and Long-term Growth PotentialNovember 7, 2024 | markets.businessinsider.comQ3 2024 Praxis Precision Medicines Inc Earnings CallNovember 7, 2024 | finance.yahoo.comPraxis Precision Medicines Reports Q3 2024 Results and ProgressNovember 7, 2024 | markets.businessinsider.comPraxis Precision Medicines (NASDAQ:PRAX) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $151.00 price target on shares of Praxis Precision Medicines in a report on Thursday.November 7, 2024 | marketbeat.comPraxis Precision Medicines' (PRAX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $120.00 target price on shares of Praxis Precision Medicines in a research report on Thursday.November 7, 2024 | marketbeat.comPraxis Precision Medicines to Participate in Three Upcoming November Investor ConferencesNovember 6, 2024 | globenewswire.comPraxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comPraxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | globenewswire.comAssenagon Asset Management S.A. Decreases Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Assenagon Asset Management S.A. lessened its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 48.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,096 sNovember 3, 2024 | marketbeat.comPraxis Precision Medicines (PRAX) to Release Quarterly Earnings on WednesdayPraxis Precision Medicines (NASDAQ:PRAX) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports.November 2, 2024 | marketbeat.comPraxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024November 1, 2024 | globenewswire.comMoody Aldrich Partners LLC Raises Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Moody Aldrich Partners LLC lifted its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 29.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,605 shares of the company's stock after purchasing anOctober 24, 2024 | marketbeat.comWe're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn RateOctober 21, 2024 | finance.yahoo.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of "Moderate Buy" from BrokeragesPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the compaOctober 21, 2024 | marketbeat.comDimensional Fund Advisors LP Trims Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Dimensional Fund Advisors LP trimmed its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 54.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,888 sharOctober 15, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week High - Here's WhyPraxis Precision Medicines (NASDAQ:PRAX) Hits New 12-Month High - Here's What HappenedOctober 14, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Millennium Management LLCMillennium Management LLC lowered its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 48.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 90,909 shares of the compaOctober 14, 2024 | marketbeat.comPraxis Precision Medicines: Great Price Movement, But Still Not ConvincedOctober 13, 2024 | seekingalpha.comPraxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in BiopharmaceuticalsOctober 12, 2024 | msn.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Bought by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company increased its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 77.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,308 sharesOctober 11, 2024 | marketbeat.comPraxis Precision Medicines Sees Unusually Large Options Volume (NASDAQ:PRAX)Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) saw unusually large options trading on Wednesday. Traders bought 5,007 put options on the company. This is an increase of approximately 718% compared to the typical daily volume of 612 put options.October 9, 2024 | marketbeat.comPraxis Precision Medicines (PRAX) Receives a Buy from Piper SandlerOctober 7, 2024 | markets.businessinsider.comTruist Financial Remains a Buy on Praxis Precision Medicines (PRAX)October 4, 2024 | markets.businessinsider.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 2.3%Praxis Precision Medicines (NASDAQ:PRAX) Trading 2.3% HigherOctober 3, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 3.6%Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.6%October 2, 2024 | marketbeat.comBiocartis appoints renowned precision oncology expert, Dr. W. Michael Korn, as Chief Medical and Scientific OfficerSeptember 30, 2024 | msn.comPerceptive Advisors LLC Decreases Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Perceptive Advisors LLC decreased its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 8.7% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 750,230 shares of the company's stock after selling 71,359 shares during tSeptember 30, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Position Boosted by Marshall Wace LLPMarshall Wace LLP increased its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 105.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 248,381 shares of the company's stocSeptember 29, 2024 | marketbeat.comFred Alger Management LLC Sells 44,446 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Fred Alger Management LLC trimmed its position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 94.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,595 shares of the company's stockSeptember 28, 2024 | marketbeat.comPoint72 Asset Management L.P. Grows Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Point72 Asset Management L.P. grew its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 10.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,051,701 shares of the companySeptember 26, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of "Moderate Buy" from AnalystsPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the compSeptember 26, 2024 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Raised by Rhumbline AdvisersRhumbline Advisers lifted its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 14,500.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,192 shares of the company's stock after purcSeptember 24, 2024 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 7.9%Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 7.9%September 23, 2024 | marketbeat.com Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. PRAX Media Mentions By Week PRAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRAX News Sentiment▼0.320.46▲Average Medical News Sentiment PRAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRAX Articles This Week▼104▲PRAX Articles Average Week Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Travere Therapeutics News Today Ligand Pharmaceuticals News Today COMPASS Pathways News Today Sage Therapeutics News Today MacroGenics News Today Repare Therapeutics News Today Crinetics Pharmaceuticals News Today Krystal Biotech News Today ADMA Biologics News Today Avidity Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRAX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
